Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Wright Reports
Provider: Pechala's Reports
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Avanir Pharmaceuticals Inc announces submission of new drug application for AVP-825 for the acute treatment of migraine

Thursday, 30 Jan 2014 09:00am EST 

Avanir Pharmaceuticals Inc:Says that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of AVP-825, its Breath Powered investigational drug-device combination product for the acute treatment of migraine. 

Company Quote

-0.64 -5.48%
19 Sep 2014